Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2009

01-04-2009 | ORIGINAL ARTICLE-THORACIC ONCOLOGY

Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center

Authors: Katja Ott, MD, Franz G. Bader, MD, Florian Lordick, MD, Marcus Feith, MD, Holger Bartels, MD, J. Ruediger Siewert, MD

Published in: Annals of Surgical Oncology | Issue 4/2009

Login to get access

Abstract

Background

Despite a considerable number of randomized studies, the surgical approach to locally advanced adenocarcinoma of the esophagogastric junction (AEG) I and II is still discussed controversially. Thus, we evaluated the surgical risk and outcome after an abdominothoracic esophagectomy (Ivor-Lewis) with intrathoracic anastomosis as standard procedure.

Methods

Between 1998 and 2006, a total of 240 consecutive patients underwent standardized right thoracoabdominal esophagectomy with two-field lymphadenectomy and intrathoracic anastomosis (Ivor-Lewis operation) for AEG I (n = 206) or AEG II (n = 34). A total of 157 patients (65.4%) had neoadjuvant chemotherapy.

Results

Postoperative morbidity occurred in 17.9% (43 of 240). Overall mortality was 3.8% (9 of 240). The majority of patients (4 of 9) died because of severe pulmonary complications (44.4%) irrespective of surgical complications. Neoadjuvant chemotherapy did not increase morbidity or mortality. The median overall survival was 51 months. Multivariate analysis including age >75 years, clinical response to chemotherapy, complications, R-category and N-category revealed R-category (P = .005; relative risk [RR] 0.32, 95% confidence interval [95% CI] 0.14–0.70) and complications (P < .001, RR 0.16, 95% CI 0.08–0.35) as independent prognostic factors for all patients. Complications was the only independent prognostic factor (P < .001, RR 0.09, 95% CI 0.08–0.35) for the R0 resected patients.

Conclusions

At an experienced center, Ivor-Lewis resection is a safe surgical procedure. Outcome of patients was significantly influenced by surgical factors such as complete resection and complications. Neoadjuvant chemotherapy did not lead to higher morbidity and mortality. The high mortality from non-surgery–related complications emphasizes the importance of careful preoperative evaluation of comorbidities and patient selection.
Literature
1.
Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.PubMedCrossRef
2.
Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg. 2001;72:306–13.PubMedCrossRef
3.
Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–9.PubMedCrossRef
4.
Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg. 1997;174:320–4.PubMedCrossRef
5.
Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg. 1993;8:367–70.CrossRef
6.
Jacobi CA, Zieren HU, Muller JM, Pichlmaier H. Surgical therapy of esophageal carcinoma: the influence of surgical approach and esophageal resection on cardiopulmonary function. Eur J Cardiothorac Surg. 1997;11:32–7.PubMedCrossRef
7.
de Boer AG, van Lanschot JJ, van Sandick JW, Hulscher JB, Stalmeier PF, de Haes JC, et al. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J Clin Oncol. 2004;22:4202–8.PubMedCrossRef
8.
Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992–1000; discussion 1000–1.
9.
Siewert JR, Stein HJ, Feith M. Surgical approach to invasive adenocarcinoma of the distal esophagus (Barrett’s cancer). World J Surg. 2003;27:1058–61.PubMedCrossRef
10.
Bader FG, Lordick F, Fink U, Becker K, Hofler H, Busch R, et al. Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up. Onkologie. 2008;31:366–72.PubMedCrossRef
11.
Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 2003;6:159–67.PubMedCrossRef
12.
Bartels H, Stein HJ, Siewert JR. Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg. 1998;85:840–4.PubMedCrossRef
13.
Bartels H, Stein HJ, Siewert JR. Risk analysis in esophageal surgery. Recent Results Cancer Res. 2000;155:89–96.PubMed
14.
Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–8.PubMedCrossRef
15.
Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–65.PubMed
16.
Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604–10.PubMedCrossRef
17.
Becker K, Mueller JD, Schulmacher C, Ott, K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30.PubMedCrossRef
18.
Kauer WK, Stein HJ, Dittler HJ, Siewert JR. Stent implantation as a treatment option in patients with thoracic anastomotic leaks after esophagectomy. Surg Endosc. 2008;22:50–3.PubMedCrossRef
19.
Green F, Page D, Fleming I. AJCC cancer staging manual,. 6th ed. New York: Springer, 2002.
20.
Bizekis C, Kent MS, Luketich JD, Buenaventura PO, Landreneau RJ, Schuchert MJ, Alvelo-Rivera M. Initial experience with minimally invasive Ivor Lewis esophagectomy. Ann Thorac Surg. 2006;82:402–6; discussion 406–7.
21.
Griffin SM, Shaw IH, Dresner SM. Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: risk factors and management. J Am Coll Surg. 2002;194:285–97.PubMedCrossRef
22.
Junemann-Ramirez M, Awan MY, Khan ZM, Rahamim JS. Anastomotic leakage post-esophagogastrectomy for esophageal carcinoma: retrospective analysis of predictive factors, management and influence on long-term survival in a high volume centre. Eur J Cardiothorac Surg. 2005;27:3–7.PubMedCrossRef
23.
Karl RC, Schreiber R, Boulware D, Baker S, Coppola D. Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg. 2000; 231:635–43.PubMedCrossRef
24.
Lozac’h P, Topart P, Perramant M. Ivor Lewis procedure for epidermoid carcinoma of the esophagus. A series of 264 patients. Semin Surg Oncol. 1997;13:238–44.PubMedCrossRef
25.
Sarela AI, Tolan DJ, Harris K, Dexter SP, Sue-Ling HM. Anastomotic leakage after esophagectomy for cancer: a mortality-free experience. J Am Coll Surg. 2008;206:516–23.PubMedCrossRef
26.
Stilidi I, Davydov M, Bokhyan V, Suleymanov E. Subtotal esophagectomy with extended 2-field lymph node dissection for thoracic esophageal cancer. Eur J Cardiothorac Surg. 2003;23:415–20.PubMedCrossRef
27.
Suttie SA, Li AG, Quinn M, Park KG. The impact of operative approach on outcome of surgery for gastro-oesophageal tumours. World J Surg Oncol. 2007;5:95.PubMedCrossRef
28.
Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Pairolero PC. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2001;71:1803–8.PubMedCrossRef
29.
Ferri LE, Law S, Wong KH, Kwok KF, Wong J. The influence of technical complications on postoperative outcome and survival after esophagectomy. Ann Surg Oncol. 2006;13:557–64.PubMedCrossRef
30.
Brucher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006;106:2119–27.PubMedCrossRef
31.
Atkins BZ, Shah AS, Hutcheson KA, Mangum JH, Pappas TN, Harpole DH, Jr., D’Amico TA. Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg. 2004;78:1170–6. discussion 1170–6.
32.
Dumont P, Wihlm JM, Hentz JG, Roeslin N, Lion R, Morand G. Respiratory complications after surgical treatment of esophageal cancer A study of 309 patients according to the type of resection. Eur J Cardiothorac Surg. 1995;9:539–43.PubMedCrossRef
33.
34.
Whooley BP, Law S, Murthy SC, Alexandrou A, Wong J. Analysis of reduced death and complication rates after esophageal resection. Ann Surg. 2001;233:338–44.PubMedCrossRef
35.
Paterson IM, Wong J. Anastomotic leakage: an avoidable complication of Lewis-Tanner oesophagectomy. Br J Surg. 1989;76:127–9.PubMedCrossRef
36.
Sauvanet A, Baltar J, Le Mee J, Belghiti J. Diagnosis and conservative management of intrathoracic leakage after oesophagectomy. Br J Surg. 1998;85:1446–9.PubMedCrossRef
37.
Urschel JD. Esophagogastrostomy anastomotic leaks complicating esophagectomy: a review. Am J Surg. 1995;169:634–40.PubMedCrossRef
38.
Liebermann-Meffert DM, Meier R, Siewert JR. Vascular anatomy of the gastric tube used for esophageal reconstruction. Ann Thorac Surg. 1992;54:1110–5.PubMedCrossRef
39.
Law SY, Fok M, Wong J. Risk analysis in resection of squamous cell carcinoma of the esophagus. World J Surg. 1994;18:339–46.PubMedCrossRef
40.
Binkert CA, Yucel EK, Davison BD, Sugarbaker DJ, Baum RA. Percutaneous treatment of high-output chylothorax with embolization or needle disruption technique. J Vasc Interv Radiol. 2005;16:1257–62.PubMed
41.
Cope C, Kaiser LR. Management of unremitting chylothorax by percutaneous embolization and blockage of retroperitoneal lymphatic vessels in 42 patients. J Vasc Interv Radiol. 2002;13:1139–48.PubMedCrossRef
42.
Bona D, Sarli D, Saino G, Quarenghi M, Bonavina L. Successful conservative management of benign gastro-bronchial fistula after intrathoracic esophagogastrostomy. Ann Thorac Surg. 2007;84:1036–8.PubMedCrossRef
43.
Orringer MB, Marshall B, Chang AC, Lee J, Pickens A, Lau CL. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246:363–72. discussion 372–4.
44.
Sakakura C, Hagiwara A, Kato D, Deguchi K, Hamada T, Itoi Y, et al. Successful treatment of intractable esophagothoracic fistula using covered self-expandable stent. Hepatogastroenterology. 2003;50:77–9.PubMed
45.
Law S, Wong KH, Kwok KF, Chu KM, Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg. 2004;240:791–800.PubMedCrossRef
46.
Ruol A, Portale G, Castoro C, Merigliano S, Cagol M, Cavallin F, et al. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol. 2007;14:3243–50.PubMedCrossRef
47.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRef
48.
Berger AC, Scott WJ, Freedman G, Konski A, Weiner L, Cheng JD, Goldberg M. Morbidity and mortality are not increased after induction chemoradiotherapy followed by esophagectomy in patients with esophageal cancer. Semin Oncol. 2005;32(6 Suppl 9): S16–20.
49.
Kelley ST, Coppola D, Karl RC. Neoadjuvant chemoradiotherapy is not associated with a higher complication rate vs. surgery alone in patients undergoing esophagectomy. J Gastrointest Surg. 2004;8:227–31; discussion 231–2.
50.
Low DE, Kunz S, Schembre D, Otero H, Malpass T, Hsi A, et al. Esophagectomy—it’s not just about mortality anymore: standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. J Gastrointest Surg. 2007;11:1395–402. discussion 1402.
51.
Bonavina L, Via A, Incarbone R, Saino G, Peracchia A. Results of surgical therapy in patients with Barrett’s adenocarcinoma. World J Surg. 2003;27:1062–6.PubMedCrossRef
52.
Lagarde SM, Maris AK, de Castro SM, Busch OR, Obertop H, van Lanschot JJ. Evaluation of O-POSSUM in predicting in-hospital mortality after resection for oesophageal cancer. Br J Surg. 2007;94:1521–6.PubMedCrossRef
53.
Lagarde SM, Reitsma JB, de Castro SM, Ten Kate FJ, Busch OR, van Lanschot JJ. Prognostic nomogram for patients undergoing oesophagectomy for adenocarcinoma of the oesophagus or gastro-oesophageal junction. Br J Surg. 2007;94:1361–8.PubMedCrossRef
54.
Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 2006;95:260–9.PubMed
Metadata
Title
Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center
Authors
Katja Ott, MD
Franz G. Bader, MD
Florian Lordick, MD
Marcus Feith, MD
Holger Bartels, MD
J. Ruediger Siewert, MD
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0336-5

Other articles of this Issue 4/2009

Annals of Surgical Oncology 4/2009 Go to the issue

Gastrointestinal Oncology

APC, MYH, and the Correlation Genotype-Phenotype in Colorectal Polyposis

Other

Lymph Node Yield as a Prognostic Factor in Cancer Studies—Due to Undersampling of Tumor-Free Lymph Nodes at Higher N Stages?

Hepatobiliary and Pancreatic Tumors

Low-Level Expression of Smad7 Correlates with Lymph Node Metastasis and Poor Prognosis in Patients with Pancreatic Cancer

Thoracic Oncology

Partial Upper Sternotomy for Anterosuperior Mediastinal Surgery: An Institutional Experience

Hepatobiliary and Pancreatic Tumors

Biology Dictates Prognosis Following Resection of Gallbladder Carcinoma: Sometimes Less is More

Hepatobiliary and Pancreatic Tumors

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma